| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Medpace Hldgs (NASDAQ:MEDP) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 6 | 1 | 2 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 0 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 4 | 0 | 2 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $433.6, a high estimate of $510.00, and a low estimate of $305.00. This upward trend is apparent, with the current average reflecting a 32.03% increase from the previous average price target of $328.40.
A clear picture of Medpace Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luke Sergott | Barclays | Lowers | Underweight | $425.00 | $450.00 |
| David Windley | Jefferies | Raises | Hold | $450.00 | $400.00 |
| Jamie Clark | Rothschild & Co | Raises | Neutral | $474.00 | $342.00 |
| Dan Leonard | UBS | Raises | Sell | $305.00 | $300.00 |
| Ann Hynes | Mizuho | Raises | Outperform | $510.00 | $328.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $436.00 | $298.00 |
| Justin Bowers | Deutsche Bank | Raises | Hold | $430.00 | $270.00 |
| Luke Sergott | Barclays | Raises | Equal-Weight | $450.00 | $300.00 |
| Eric Coldwell | Baird | Raises | Neutral | $490.00 | $313.00 |
| Charles Rhyee | TD Cowen | Raises | Sell | $366.00 | $283.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Medpace Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Medpace Hldgs analyst ratings.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Medpace Hldgs's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 14.24%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Medpace Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 14.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Medpace Hldgs's ROE excels beyond industry benchmarks, reaching 23.57%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Medpace Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.2%, the company showcases efficient use of assets and strong financial health.
Debt Management: Medpace Hldgs's debt-to-equity ratio is below the industry average at 0.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MEDP
